Strategies Wealth Advisors LLC Invests $366,000 in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Strategies Wealth Advisors LLC purchased a new stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 25,000 shares of the company’s stock, valued at approximately $366,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legal & General Group Plc grew its position in shares of Contineum Therapeutics by 74.0% during the 4th quarter. Legal & General Group Plc now owns 3,631 shares of the company’s stock worth $53,000 after buying an additional 1,544 shares during the period. Corebridge Financial Inc. grew its holdings in Contineum Therapeutics by 73.1% during the 4th quarter. Corebridge Financial Inc. now owns 5,215 shares of the company’s stock worth $76,000 after acquiring an additional 2,202 shares during the period. BNP Paribas Financial Markets raised its position in shares of Contineum Therapeutics by 1,248.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,743 shares of the company’s stock valued at $129,000 after acquiring an additional 6,243 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Contineum Therapeutics by 36.3% in the 4th quarter. Rhumbline Advisers now owns 8,233 shares of the company’s stock valued at $121,000 after purchasing an additional 2,191 shares during the period. Finally, Barclays PLC boosted its position in shares of Contineum Therapeutics by 248.6% in the 3rd quarter. Barclays PLC now owns 8,308 shares of the company’s stock worth $158,000 after purchasing an additional 5,925 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have weighed in on CTNM. Jones Trading assumed coverage on Contineum Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $23.00 target price on the stock. Robert W. Baird reduced their price objective on shares of Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Contineum Therapeutics in a research note on Friday, March 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price target on shares of Contineum Therapeutics in a research report on Thursday, January 9th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $24.80.

Contineum Therapeutics Stock Performance

Shares of CTNM stock opened at $4.01 on Monday. The company has a market capitalization of $103.75 million and a P/E ratio of -0.82. Contineum Therapeutics, Inc. has a 52 week low of $3.91 and a 52 week high of $22.00. The company’s 50 day moving average price is $6.97 and its two-hundred day moving average price is $12.11.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).